Cargando…

Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases

Recent studies have shown that a number of common autoimmune diseases have perturbations of their intestinal microbiome (dysbiosis). These include: Celiac Disease (CeD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Sjogren’s Syndrome (SS), and Type 1 diabetes (T1D). All of these have intestin...

Descripción completa

Detalles Bibliográficos
Autores principales: Marietta, Eric, Mangalam, Ashutosh K., Taneja, Veena, Murray, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655733/
https://www.ncbi.nlm.nih.gov/pubmed/33193357
http://dx.doi.org/10.3389/fimmu.2020.573079
_version_ 1783608234794287104
author Marietta, Eric
Mangalam, Ashutosh K.
Taneja, Veena
Murray, Joseph A.
author_facet Marietta, Eric
Mangalam, Ashutosh K.
Taneja, Veena
Murray, Joseph A.
author_sort Marietta, Eric
collection PubMed
description Recent studies have shown that a number of common autoimmune diseases have perturbations of their intestinal microbiome (dysbiosis). These include: Celiac Disease (CeD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Sjogren’s Syndrome (SS), and Type 1 diabetes (T1D). All of these have intestinal microbiomes that are different from healthy controls. There have been numerous studies using animal models of single probiotics (monoclonal) or mixtures of probiotics (polyclonal) and even complete microbiota transfer (fecal microbial transfer-FMT) to inhibit or delay the onset of autoimmune diseases such as the aforementioned common ones. However, proportionally, fewer clinical trials have utilized monoclonal therapies or FMT than polyclonal therapies for treating autoimmune diseases, even though bacterial mono-therapies do inhibit the development of autoimmune diseases and/or delay the onset of autoimmune diseases in rodent models of those autoimmune diseases. In this review then, we review the previously completed and currently ongoing clinical trials that are testing bacterial therapies (FMT, monoclonal, and polyclonal) to treat common autoimmune dseases and discuss the successes in using bacterial monotherapies to treat rodent models of these common autoimmune diseases.
format Online
Article
Text
id pubmed-7655733
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76557332020-11-13 Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases Marietta, Eric Mangalam, Ashutosh K. Taneja, Veena Murray, Joseph A. Front Immunol Immunology Recent studies have shown that a number of common autoimmune diseases have perturbations of their intestinal microbiome (dysbiosis). These include: Celiac Disease (CeD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Sjogren’s Syndrome (SS), and Type 1 diabetes (T1D). All of these have intestinal microbiomes that are different from healthy controls. There have been numerous studies using animal models of single probiotics (monoclonal) or mixtures of probiotics (polyclonal) and even complete microbiota transfer (fecal microbial transfer-FMT) to inhibit or delay the onset of autoimmune diseases such as the aforementioned common ones. However, proportionally, fewer clinical trials have utilized monoclonal therapies or FMT than polyclonal therapies for treating autoimmune diseases, even though bacterial mono-therapies do inhibit the development of autoimmune diseases and/or delay the onset of autoimmune diseases in rodent models of those autoimmune diseases. In this review then, we review the previously completed and currently ongoing clinical trials that are testing bacterial therapies (FMT, monoclonal, and polyclonal) to treat common autoimmune dseases and discuss the successes in using bacterial monotherapies to treat rodent models of these common autoimmune diseases. Frontiers Media S.A. 2020-10-28 /pmc/articles/PMC7655733/ /pubmed/33193357 http://dx.doi.org/10.3389/fimmu.2020.573079 Text en Copyright © 2020 Marietta, Mangalam, Taneja and Murray http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Marietta, Eric
Mangalam, Ashutosh K.
Taneja, Veena
Murray, Joseph A.
Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title_full Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title_fullStr Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title_full_unstemmed Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title_short Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
title_sort intestinal dysbiosis in, and enteral bacterial therapies for, systemic autoimmune diseases
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655733/
https://www.ncbi.nlm.nih.gov/pubmed/33193357
http://dx.doi.org/10.3389/fimmu.2020.573079
work_keys_str_mv AT mariettaeric intestinaldysbiosisinandenteralbacterialtherapiesforsystemicautoimmunediseases
AT mangalamashutoshk intestinaldysbiosisinandenteralbacterialtherapiesforsystemicautoimmunediseases
AT tanejaveena intestinaldysbiosisinandenteralbacterialtherapiesforsystemicautoimmunediseases
AT murrayjosepha intestinaldysbiosisinandenteralbacterialtherapiesforsystemicautoimmunediseases